HRA006855
Title:
Phosphorylation of AGO2 by TBK1 promotes the formation of oncogenic miRISC in NSCLC
Release date:
2024-03-13
Description:
Non-small-cell lung cancer (NSCLC) is a highly lethal tumor that often develops resistance to targeted therapy. We show that Tank-binding kinase 1 (TBK1) phosphorylates AGO2 at S417 (pS417-AGO2), which promotes NSCLC progression by increasing the formation of microRNA-induced silencing complex (miRISC). High levels of pS417-AGO2 in clinical NSCLC specimens are positively associated with poor prognosis. Interestingly, the treatment with EGFR inhibitor Gefitinib can significantly induce pS417-AGO2, thereby increasing the formation and activity of oncogenic miRISC, which may contribute to NSCLC resistance to Gefitinib. Based on these, we have developed two therapeutic strategies. One is jointly to antagonize multiple oncogenic miRNAs highly expressed in NSCLC and use TBK1 inhibitor Amlexanox reducing the formation of oncogenic miRISC. Another approach is to combine Gefitinib with Amlexanox to inhibit the progression of Gefitinib-resistant NSCLC.
Data Accessibility:   
Open access
BioProject:
Study type:
Cell line related study
Dataset Download
MetaData:
Files:
Aspera Command Line:  Help   

 Note: HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client) or Asepra Command Line.

Individuals & samples
Files
Submitter:   Yu jianxiu / jianxiu.yu@gmail.com
Organization:   Shanghai Jiao Tong University School of Medicine
Submission date:   2024-03-11